The Federal Floor
State-level peptide regulation operates against a federal baseline established by three statutes and one regulatory posture. The Federal Food, Drug, and Cosmetic Act (FDCA) classifies any compound intended for human use that is not an approved drug as a misbranded or unapproved new drug, subjecting interstate commerce in such compounds to FDA jurisdiction. The Controlled Substances Act (CSA) does not currently schedule most research peptides — BPC-157, TB-500, Ipamorelin, CJC-1295 are not scheduled — but specific peptides have been scheduled (e.g., certain growth hormone analogs in some jurisdictions). The Anti-Drug Abuse Act and its progeny establish penalties for distribution and manufacturing of unapproved drugs in commerce. The FDA's posture is to enforce primarily against vendors and manufacturers, with documented enforcement actions against suppliers but vanishingly rare action against individual end-users.
State laws layer on top of the federal floor. States generally cannot make legal what federal law prohibits, but they can make additional acts illegal, regulate practitioners (clinics, compounding pharmacies) more strictly, or designate specific compounds under state-level controlled-substance schedules independent of federal scheduling.
Enforcement Patterns We Have Documented
Across approximately three years of monitoring, the patterns of actual enforcement at the state level fall into three categories. Direct individual prosecution for personal possession or use of research peptides: we cannot identify a single documented case in any U.S. state. Action against clinics or providers prescribing peptides in regulatory gray areas: happens occasionally, particularly in California, Texas, Florida, and New York where state medical boards have begun scrutinizing peptide therapy clinics. Action against vendors operating physically within a state: rare but documented, generally driven by FDA referral or by separate predicate offenses (financial fraud, unrelated import violations).
The practical implication for individual researchers is that the legal risk profile differs by what you do, not primarily by where you live. Ordering small quantities for personal research carries minimal documented enforcement risk in any state. Operating as an unlicensed compounder, prescribing as an unlicensed provider, or operating a vendor business carries substantial risk in any state.
States Where Practitioner Scrutiny Has Intensified
Five states have seen meaningful state medical board action against peptide therapy clinics in the past three years. California: the Medical Board has issued multiple advisories on off-label prescription of compounds without FDA approval, with several actions against clinics making aggressive claims. Texas: the Texas Medical Board has brought disciplinary proceedings against several providers for prescribing or dispensing unapproved peptides. Florida: the Department of Health has investigated several anti-aging and wellness clinics offering peptide injections. New York: the State Education Department's Office of Professional Discipline has acted against several providers. Arizona: the Naturopathic Physicians Medical Board has taken action against naturopathic providers prescribing research peptides outside their scope.
The relevance to individual researchers: if your peptide acquisition strategy depends on a clinic prescription, the regulatory environment around your provider is shifting. Several clinics that were operating openly in 2022-2023 have changed their offerings, retreated to compound-pharmacy-only models, or shut down entirely.
States With Schedule Additions or Enhanced Restrictions
The CSA schedule is federal, but states can add to it. A small number of states have separately scheduled or restricted compounds that are also research peptides. Florida has scheduled certain growth hormone secretagogues under state controlled substance law in some interpretations. Idaho and Louisiana have enacted controlled-substance schedule additions that touch some peptide compounds; the interaction with federal law and the practical enforcement posture is unsettled. Most states have not separately scheduled research peptides.
Customs and Interstate Shipping
The vast majority of enforcement-relevant action around research peptide acquisition occurs at the border, not at the state line. Packages entering the U.S. from foreign manufacturers can be inspected by Customs and Border Protection, with peptide-recognizable shipments subject to seizure under FDCA authority. The state into which the package is destined is largely irrelevant to whether CBP seizes; the relevance is post-seizure correspondence. CBP will typically issue a notice of seizure with an option to claim or abandon the property. Most individual recipients abandon, because contesting requires acknowledging intended human use, which creates new exposure.
Interstate shipments within the U.S. — domestic vendor to domestic researcher — are not routinely intercepted, and we are not aware of any documented enforcement actions against individual recipients of domestic peptide shipments. The risk for U.S.-to-U.S. shipments is on the vendor side, and the documented enforcement cases against U.S.-based research-peptide vendors involve FDA action driven by marketing claims that crossed into explicit human-use representations.
Practical Conclusions, By Posture
End-User / Personal Researcher
- Legal posture across all 50 states is functionally similar: gray area, minimal documented individual enforcement.
- Avoid quantities or behavior that would suggest intent to distribute (large bulk orders, repackaging, reselling).
- Customs seizure risk is real but the consequences are typically limited to loss of the shipment.
- Domestic vendor relationships carry lower seizure risk than international.
Provider / Clinic / Pharmacy
- State-level regulatory environment is hardening, particularly in CA, TX, FL, NY, AZ.
- Compounding pharmacy regulations under 503A and 503B are the practical constraint; operate outside them at substantial risk.
- Marketing claims drive enforcement attention more than the underlying clinical activity.
- State board action is more likely than federal criminal action and more devastating to the practice.
What Is Not Stable
State law on peptides is changing more rapidly now than at any prior point we have tracked. The combination of GLP-1 popularity (Ozempic/Wegovy/Mounjaro), the rise of "longevity clinics" using peptide protocols, and the increased visibility of research peptide use in non-medical contexts has begun to generate legislative attention. We expect substantial additional state-level activity in 2026-2027, particularly around clinical practice regulation and compounding pharmacy oversight. The end-user landscape is more stable than the provider landscape, but neither should be treated as fixed.
The legal information on this page reflects the editorial desk's understanding as of December 2025. Statutes change. Enforcement priorities shift. Court decisions reinterpret existing law. This is journalism, not legal advice. Individual researchers facing specific legal questions should retain counsel licensed in the relevant jurisdiction before making decisions.
Where To Go From Here
Reading any individual page on this site is a slice of the picture. The full investigation continues across the related desks. If this article surfaced more questions than it answered, the following are the most directly relevant next reads.
Editorial Standards
This report is updated periodically. Discrepancies between our reporting and reality are taken seriously — if you have observed something that contradicts what is published here, send it to the editorial desk with documentation and we will revise. Our reporting is constrained by what can be sourced, verified, or directly observed. Where evidence is weak we say so. Where it is absent we do not invent.
Wild West & Peptides receives no compensation from any vendor mentioned in this report, runs no affiliate program, and has no commercial relationship with the research-peptide industry it covers.